BRPI0817130A2 - Composto, sal ou solvato farmaceuticamente aceitáveis ou uma mistura dos mesmos; composição farmacêutica, composição farmacêutica embalada; método para tratar um paciente, aumentar a sensibilidade das células cancerígenas à quimioterapia, reduzir erros de medição e melhorar a conformidade terapêutica, inibir a hidrólise atp e a atividade das células b e determinar a presença de btk - Google Patents
Composto, sal ou solvato farmaceuticamente aceitáveis ou uma mistura dos mesmos; composição farmacêutica, composição farmacêutica embalada; método para tratar um paciente, aumentar a sensibilidade das células cancerígenas à quimioterapia, reduzir erros de medição e melhorar a conformidade terapêutica, inibir a hidrólise atp e a atividade das células b e determinar a presença de btkInfo
- Publication number
- BRPI0817130A2 BRPI0817130A2 BRPI0817130A BRPI0817130A2 BR PI0817130 A2 BRPI0817130 A2 BR PI0817130A2 BR PI0817130 A BRPI0817130 A BR PI0817130A BR PI0817130 A2 BRPI0817130 A2 BR PI0817130A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- btk
- solvate
- chemotherapy
- patient
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title 2
- 206010028980 Neoplasm Diseases 0.000 title 1
- 201000011510 cancer Diseases 0.000 title 1
- 238000002512 chemotherapy Methods 0.000 title 1
- 150000001875 compounds Chemical class 0.000 title 1
- 230000000694 effects Effects 0.000 title 1
- 230000007062 hydrolysis Effects 0.000 title 1
- 238000006460 hydrolysis reaction Methods 0.000 title 1
- 230000002401 inhibitory effect Effects 0.000 title 1
- 238000005259 measurement Methods 0.000 title 1
- 238000000034 method Methods 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
- 230000035945 sensitivity Effects 0.000 title 1
- 239000012453 solvate Substances 0.000 title 1
- 230000001225 therapeutic effect Effects 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Hematology (AREA)
- Neurology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US97399507P | 2007-09-20 | 2007-09-20 | |
| US5077708P | 2008-05-06 | 2008-05-06 | |
| PCT/US2008/077054 WO2009039397A2 (en) | 2007-09-20 | 2008-09-19 | Substituted amides, methods of making, use thereof for the treatment of diseases such as cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0817130A2 true BRPI0817130A2 (pt) | 2015-03-31 |
Family
ID=40377565
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0817130 BRPI0817130A2 (pt) | 2007-09-20 | 2008-09-19 | Composto, sal ou solvato farmaceuticamente aceitáveis ou uma mistura dos mesmos; composição farmacêutica, composição farmacêutica embalada; método para tratar um paciente, aumentar a sensibilidade das células cancerígenas à quimioterapia, reduzir erros de medição e melhorar a conformidade terapêutica, inibir a hidrólise atp e a atividade das células b e determinar a presença de btk |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US7884108B2 (enExample) |
| EP (1) | EP2188267B1 (enExample) |
| JP (1) | JP5485894B2 (enExample) |
| KR (1) | KR20100072032A (enExample) |
| CN (1) | CN101861307B (enExample) |
| AR (1) | AR068503A1 (enExample) |
| AU (1) | AU2008302099B2 (enExample) |
| BR (1) | BRPI0817130A2 (enExample) |
| CA (1) | CA2700443A1 (enExample) |
| CL (1) | CL2008002793A1 (enExample) |
| PE (1) | PE20091201A1 (enExample) |
| RU (1) | RU2470923C2 (enExample) |
| TW (1) | TWI423966B (enExample) |
| WO (1) | WO2009039397A2 (enExample) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR063706A1 (es) * | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| US7838523B2 (en) * | 2006-09-11 | 2010-11-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| US7683064B2 (en) | 2008-02-05 | 2010-03-23 | Roche Palo Alto Llc | Inhibitors of Bruton's tyrosine kinase |
| UA103319C2 (en) | 2008-05-06 | 2013-10-10 | Глаксосмитклайн Ллк | Thiazole- and oxazole-benzene sulfonamide compounds |
| US8426424B2 (en) * | 2008-05-06 | 2013-04-23 | Cgi Pharmaceuticals, Inc. | Certain substituted amides, method of making, and method of use thereof |
| UA103327C2 (en) | 2008-06-24 | 2013-10-10 | Ф. Хоффманн-Ля Рош Аг | Substituted pyridin-2-ones and pyridazin-3-ones |
| MX2010013478A (es) | 2008-07-02 | 2010-12-20 | Hoffmann La Roche | Nuevas fenilpirazinonas como inhibidores de cinasa. |
| SG185462A1 (en) | 2010-05-07 | 2012-12-28 | Gilead Connecticut Inc | Pyridone and aza-pyridone compounds and methods of use |
| CN106220614B (zh) * | 2010-09-01 | 2019-07-16 | 吉利德康涅狄格有限公司 | 吡啶酮/吡嗪酮、其制备方法及使用方法 |
| UA111756C2 (uk) | 2011-11-03 | 2016-06-10 | Ф. Хоффманн-Ля Рош Аг | Сполуки гетероарилпіридону та азапіридону як інгібітори тирозинкінази брутона |
| BR112014010439A2 (pt) * | 2011-11-03 | 2017-04-18 | F Hoffmann - La Roche Ag | compostos, composição farmacêutica, processo de produção, método de tratamento de uma doença ou distúrbio, métodos, kit e uso de uma composição farmacêutica |
| TWI553004B (zh) | 2011-11-03 | 2016-10-11 | 建南德克公司 | ８－氟基呔－１（２ｈ）－酮化合物 |
| BR112014010391A2 (pt) | 2011-11-03 | 2017-04-18 | Hoffmann La Roche | composto, composição farmacêutica, processo de produção de uma composição farmacêutica, método de tratamento, kit e uso de uma composição farmacêutica |
| WO2013097052A1 (en) | 2011-12-30 | 2013-07-04 | Abbott Laboratories | Bromodomain inhibitors |
| JP6248048B2 (ja) | 2012-01-09 | 2017-12-13 | エックス−アールエックス，インコーポレーテッド | キナーゼ阻害活性を有するトリプトリン誘導体及びその使用 |
| WO2013157021A1 (en) | 2012-04-20 | 2013-10-24 | Advinus Therapeutics Limited | Bicyclic compounds, compositions and medicinal applications thereof |
| WO2014108820A1 (en) * | 2013-01-08 | 2014-07-17 | Aurigene Discovery Technologies Limited | Substituted 2-pyrazinone derivatives as kinase inhibitors |
| WO2014125410A1 (en) * | 2013-02-12 | 2014-08-21 | Aurigene Discovery Technologies Limited | N-substituted heterocyclic derivatives as kinase inhibitors |
| CA2903288C (en) * | 2013-03-15 | 2021-09-21 | Deciphera Pharmaceuticals, Llc | N-acyl-n'-(pyridin-2-yl) ureas and analogs exhibiting anti-cancer and anti-proliferative activities |
| BR112015025260B1 (pt) | 2013-04-25 | 2021-11-03 | Beigene, Ltd | Compostos heterocíclicos fundidos como inibidores da proteína quinase, sua composição, combinação e uso |
| DK3010543T3 (da) * | 2013-06-19 | 2025-12-01 | Som Innovation Biotech S A | Terapeutiske midler til anvendelse i profylakse og/eller behandling af hyperkinetiske bevægelsesforstyrrelser |
| CA2912359A1 (en) * | 2013-07-03 | 2015-01-08 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone amide compounds |
| PT3027171T (pt) | 2013-07-30 | 2020-06-18 | Gilead Connecticut Inc | Formulação de inibidores da syk |
| KR101810798B1 (ko) | 2013-07-30 | 2017-12-19 | 질레드 코네티컷 인코포레이티드 | Ｓｙｋ 억제제의 다형체 |
| HRP20221262T1 (hr) | 2013-09-13 | 2022-12-09 | Beigene Switzerland Gmbh | Protutijela anti-pd1 i njihova uporaba kao terapeutskih i dijagnostičkih sredstava |
| EA035727B1 (ru) * | 2013-10-18 | 2020-07-31 | Селджен Квонтисел Рисёрч, Инк. | Ингибиторы бромодомена |
| EP2876124B1 (de) | 2013-11-20 | 2019-01-09 | Uhde Inventa-Fischer GmbH | Verfahren sowie vorrichtung zur herstellung einer kristallisierbaren polymilchsäuremischung sowie polymilchsäuremischung |
| MX375752B (es) | 2013-12-05 | 2025-03-06 | Pharmacyclics Llc | Inhibidores de tirosina quinasa de bruton. |
| CA2929918C (en) | 2013-12-05 | 2018-01-23 | F. Hoffmann-La Roche Ag | Heteroaryl pyridone and aza-pyridone compounds with electrophilic functionality |
| TWI735853B (zh) | 2013-12-23 | 2021-08-11 | 美商克洛諾斯生技有限公司 | 脾酪胺酸激酶抑制劑 |
| WO2015151006A1 (en) | 2014-03-29 | 2015-10-08 | Lupin Limited | Substituted purine compounds as btk inhibitors |
| WO2015170266A1 (en) | 2014-05-07 | 2015-11-12 | Lupin Limited | Substituted pyrimidine compounds as btk inhibitors |
| ES2812626T3 (es) | 2014-06-27 | 2021-03-17 | Celgene Quanticel Res Inc | Inhibidores de la desmetilasa 1 específica de lisina |
| SG11201610975RA (en) * | 2014-07-03 | 2017-01-27 | Celgene Quanticel Res Inc | Inhibitors of lysine specific demethylase-1 |
| CN110156892B (zh) | 2014-07-03 | 2023-05-16 | 百济神州有限公司 | 抗pd-l1抗体及其作为治疗剂及诊断剂的用途 |
| EP3265453B1 (en) * | 2015-03-05 | 2022-06-29 | Boehringer Ingelheim International GmbH | New pyridinones and isoquinolinones as inhibitors of the bromodomain brd9 |
| MA52119A (fr) | 2015-10-19 | 2018-08-29 | Ncyte Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
| PT3377488T (pt) | 2015-11-19 | 2022-11-21 | Incyte Corp | Compostos heterocíclicos como imunomoduladores |
| SI3394033T1 (sl) | 2015-12-22 | 2021-03-31 | Incyte Corporation | Heterociklične spojine kot imunomodulatorji |
| CN107033069B (zh) | 2016-02-04 | 2022-03-04 | 中国科学院合肥物质科学研究院 | 一种新型布鲁顿酪氨酸激酶不可逆抑制剂 |
| KR20200118507A (ko) | 2016-02-29 | 2020-10-15 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나제의 억제제를 포함하는 투여량 형태 조성물 |
| SG11201808003RA (en) | 2016-04-15 | 2018-10-30 | Abbvie Inc | Bromodomain inhibitors |
| WO2017192961A1 (en) | 2016-05-06 | 2017-11-09 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| EP3464279B1 (en) | 2016-05-26 | 2021-11-24 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| PL3472167T3 (pl) * | 2016-06-20 | 2022-12-19 | Incyte Corporation | Związki heterocykliczne jako immunomodulatory |
| NZ749997A (en) | 2016-07-05 | 2022-11-25 | Beigene Ltd | Combination of a pd-l antagonist and a raf inhibitor for treating cancer |
| EP3484866B1 (en) | 2016-07-14 | 2022-09-07 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| WO2018033853A2 (en) | 2016-08-16 | 2018-02-22 | Beigene, Ltd. | Crystalline form of (s)-7-(1-acryloylpiperidin-4-yl)-2-(4-phenoxyphenyl)-4,5,6,7-tetra-hydropyrazolo[1,5-a]pyrimidine-3-carboxamide, preparation, and uses thereof |
| TWI739887B (zh) | 2016-08-19 | 2021-09-21 | 英屬開曼群島商百濟神州有限公司 | 使用包含btk抑制劑的組合產品治療癌症 |
| ES2941716T3 (es) | 2016-08-29 | 2023-05-25 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
| AU2017326558B2 (en) | 2016-09-19 | 2022-01-06 | Mei Pharma, Inc. | Combination therapy |
| US10842878B2 (en) | 2016-11-22 | 2020-11-24 | Dana-Farber Cancer Institute, Inc. | Degradation of Bruton's tyrosine kinase (BTK) by conjugation of BTK inhibitors with E3 ligase ligand and methods of use |
| WO2018119286A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Bicyclic heteroaromatic compounds as immunomodulators |
| EP3558973B1 (en) | 2016-12-22 | 2021-09-15 | Incyte Corporation | Pyridine derivatives as immunomodulators |
| KR102696516B1 (ko) | 2016-12-22 | 2024-08-22 | 인사이트 코포레이션 | 면역조절제로서의 벤조옥사졸 유도체 |
| MY197501A (en) | 2016-12-22 | 2023-06-19 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
| US20180179201A1 (en) | 2016-12-22 | 2018-06-28 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| CN110139641B (zh) * | 2016-12-28 | 2022-09-09 | 富士胶片富山化学株式会社 | 外用组合物 |
| EP3573989A4 (en) | 2017-01-25 | 2020-11-18 | Beigene, Ltd. | CRYSTALLINE FORMS OF (S) -7- (1- (BUT-2-YNOYL) PIPERIDIN-4-YL) -2- (4-PHENOXYPHENYL) -4, 5, 6, 7-TETRAHY DROPYRAZOLO [1, 5-A ] PYRIMIDINE-3-CARBOXAMIDE, PREPARATION AND ASSOCIATED USES |
| CN110709702A (zh) | 2017-03-24 | 2020-01-17 | 豪夫迈·罗氏有限公司 | 治疗自身免疫性疾病和炎性疾病的方法 |
| TWI877099B (zh) | 2017-06-26 | 2025-03-21 | 英屬開曼群島商百濟神州有限公司 | 抗ｐｄ－１抗體或其抗原結合片段在製備治療用於患有肝細胞癌（ｈｃｃ）之藥物的用途 |
| WO2019034009A1 (en) | 2017-08-12 | 2019-02-21 | Beigene, Ltd. | BTK INHIBITOR WITH ENHANCED DOUBLE SELECTIVITY |
| KR20220070056A (ko) | 2017-08-25 | 2022-05-27 | 길리애드 사이언시즈, 인코포레이티드 | Syk 억제제의 다형체 |
| KR102613433B1 (ko) | 2017-10-11 | 2023-12-13 | 주식회사 대웅제약 | 신규한 페닐피리딘 유도체 및 이를 포함하는 약학 조성물 |
| US11786529B2 (en) | 2017-11-29 | 2023-10-17 | Beigene Switzerland Gmbh | Treatment of indolent or aggressive B-cell lymphomas using a combination comprising BTK inhibitors |
| WO2019148150A1 (en) * | 2018-01-29 | 2019-08-01 | Dana-Farber Cancer Institute, Inc. | Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use |
| EP4212529B1 (en) | 2018-03-30 | 2025-01-29 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
| FI4219492T3 (fi) | 2018-05-11 | 2025-02-17 | Incyte Corp | Heterosyklisiä yhdisteitä immunomodulaattoreina |
| JP2022521413A (ja) | 2019-02-22 | 2022-04-07 | クロノス バイオ インコーポレイテッド | Ｓｙｋ阻害剤としての縮合ピラジンの固体形態 |
| TWI856111B (zh) | 2019-06-10 | 2024-09-21 | 瑞士商百濟神州瑞士有限責任公司 | 一種含有布魯頓氏酪胺酸激酶抑制劑的口服固體錠劑及其製備方法 |
| CA3150434A1 (en) | 2019-08-09 | 2021-02-18 | Incyte Corporation | Salts of a pd-1/pd-l1 inhibitor |
| AR120109A1 (es) | 2019-09-30 | 2022-02-02 | Incyte Corp | Compuestos de pirido[3,2-d]pirimidina como inmunomoduladores |
| IL292524A (en) | 2019-11-11 | 2022-06-01 | Incyte Corp | Salts and crystalline forms of a pd-1/pd-l1 inhibitor |
| WO2021093817A1 (zh) * | 2019-11-15 | 2021-05-20 | 杭州和正医药有限公司 | 免疫调节化合物、组合物及其应用 |
| CN114380841A (zh) * | 2020-10-19 | 2022-04-22 | 南京正大天晴制药有限公司 | 作为akt抑制剂的三环喹唑啉或二氢喹唑啉化合物 |
| US11780836B2 (en) | 2020-11-06 | 2023-10-10 | Incyte Corporation | Process of preparing a PD-1/PD-L1 inhibitor |
| WO2022099075A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Crystalline form of a pd-1/pd-l1 inhibitor |
| PE20231438A1 (es) | 2020-11-06 | 2023-09-14 | Incyte Corp | Proceso para hacer un inhibidor de pd-1/pd-l1 y sales y formas cristalinas del mismo |
| US11786531B1 (en) | 2022-06-08 | 2023-10-17 | Beigene Switzerland Gmbh | Methods of treating B-cell proliferative disorder |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR042586A1 (es) * | 2001-02-15 | 2005-06-29 | Sugen Inc | 3-(4-amidopirrol-2-ilmetiliden)-2-indolinona como inhibidores de la protein quinasa; sus composiciones farmaceuticas; un metodo para la modulacion de la actividad catalitica de la proteinquinasa; un metodo para tratar o prevenir una afeccion relacionada con la proteinquinasa |
| US7405295B2 (en) * | 2003-06-04 | 2008-07-29 | Cgi Pharmaceuticals, Inc. | Certain imidazo[1,2-a]pyrazin-8-ylamines and method of inhibition of Bruton's tyrosine kinase by such compounds |
| CN101223141A (zh) * | 2005-03-10 | 2008-07-16 | Cgi药品股份有限公司 | 特定取代的酰胺，其制备方法和使用方法 |
| AR063706A1 (es) * | 2006-09-11 | 2009-02-11 | Cgi Pharmaceuticals Inc | Determinadas amidas sustituidas, el uso de las mismas para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de btk y composiciones farmaceuticas que las comprenden. |
| US20100160292A1 (en) * | 2006-09-11 | 2010-06-24 | Cgi Pharmaceuticals, Inc | Kinase Inhibitors, and Methods of Using and Identifying Kinase Inhibitors |
-
2008
- 2008-09-17 CL CL2008002793A patent/CL2008002793A1/es unknown
- 2008-09-19 RU RU2010115574/04A patent/RU2470923C2/ru active
- 2008-09-19 BR BRPI0817130 patent/BRPI0817130A2/pt not_active Application Discontinuation
- 2008-09-19 KR KR1020107008468A patent/KR20100072032A/ko not_active Withdrawn
- 2008-09-19 CA CA2700443A patent/CA2700443A1/en not_active Abandoned
- 2008-09-19 AR ARP080104094A patent/AR068503A1/es unknown
- 2008-09-19 JP JP2010526003A patent/JP5485894B2/ja active Active
- 2008-09-19 TW TW097136216A patent/TWI423966B/zh not_active IP Right Cessation
- 2008-09-19 PE PE2008001640A patent/PE20091201A1/es not_active Application Discontinuation
- 2008-09-19 US US12/234,281 patent/US7884108B2/en active Active
- 2008-09-19 AU AU2008302099A patent/AU2008302099B2/en not_active Ceased
- 2008-09-19 CN CN2008801161200A patent/CN101861307B/zh active Active
- 2008-09-19 WO PCT/US2008/077054 patent/WO2009039397A2/en not_active Ceased
- 2008-09-19 EP EP08832237.5A patent/EP2188267B1/en active Active
-
2010
- 2010-11-04 US US12/939,518 patent/US8247550B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2009039397A3 (en) | 2009-05-22 |
| US20090082330A1 (en) | 2009-03-26 |
| JP5485894B2 (ja) | 2014-05-07 |
| EP2188267B1 (en) | 2016-08-03 |
| AU2008302099A1 (en) | 2009-03-26 |
| JP2010540452A (ja) | 2010-12-24 |
| US7884108B2 (en) | 2011-02-08 |
| CA2700443A1 (en) | 2009-03-26 |
| US8247550B2 (en) | 2012-08-21 |
| RU2010115574A (ru) | 2011-10-27 |
| RU2470923C2 (ru) | 2012-12-27 |
| EP2188267A2 (en) | 2010-05-26 |
| CL2008002793A1 (es) | 2009-09-04 |
| WO2009039397A2 (en) | 2009-03-26 |
| KR20100072032A (ko) | 2010-06-29 |
| AR068503A1 (es) | 2009-11-18 |
| TW200914446A (en) | 2009-04-01 |
| TWI423966B (zh) | 2014-01-21 |
| CN101861307A (zh) | 2010-10-13 |
| CN101861307B (zh) | 2013-05-01 |
| AU2008302099B2 (en) | 2013-03-28 |
| PE20091201A1 (es) | 2009-09-13 |
| US20110059944A1 (en) | 2011-03-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BRPI0817130A2 (pt) | Composto, sal ou solvato farmaceuticamente aceitáveis ou uma mistura dos mesmos; composição farmacêutica, composição farmacêutica embalada; método para tratar um paciente, aumentar a sensibilidade das células cancerígenas à quimioterapia, reduzir erros de medição e melhorar a conformidade terapêutica, inibir a hidrólise atp e a atividade das células b e determinar a presença de btk | |
| Tomaselli et al. | Epigenetic polypharmacology: a new frontier for epi‐drug discovery | |
| Shah et al. | Repurposing old drugs in oncology: Opportunities with clinical and regulatory challenges ahead | |
| BR112015007182A2 (pt) | inibidores de gdf-8 | |
| AR087545A1 (es) | 1h-imidazo[4,5-c]quinolina sustituidos con actividad inhibitoria de bromodominio | |
| ATE557015T1 (de) | 3,4-diarylpyrazole als proteinkinaseinhibitoren | |
| EP2506850A4 (en) | METHOD FOR THE ADMINISTRATION OF PIRFENIDON THERAPY | |
| BRPI0508461B8 (pt) | diaminopirimidinas, seus usos, e composição farmacêutica | |
| HRP20191617T1 (hr) | Kombinacija koja sadrži inhibitor mek i inhibitor b-raf | |
| BR112014017985A8 (pt) | Combinação de um inibidor de rtk com um antiestrogênio e uso da mesma para o tratamento de cancer | |
| US20230158002A1 (en) | Methods and compositions for treatment of myelodysplastic syndromes and/or acute myeloid leukemias | |
| CY1119597T1 (el) | Συνθεσεις και μεθοδοι για υπερκεραση αντοχης σε τραμαδολη | |
| Richardson et al. | Deacetylase inhibitors as a novel modality in the treatment of multiple myeloma | |
| Bureta et al. | Synergistic effect of arsenic trioxide, vismodegib and temozolomide on glioblastoma | |
| Gouda et al. | A phase I/II study of the safety and efficacy of telaglenastat (CB-839) in combination with nivolumab in patients with metastatic melanoma, renal cell carcinoma, and non-small-cell lung cancer | |
| CA2978204A1 (en) | Fixed dose combinations and formulations comprising etc1002 and ezetimibe and methods of treating or reducing the risk of cardiovascular disease | |
| CN107206090A (zh) | 阿匹莫德在结肠直肠癌治疗中的用途 | |
| MX2012013879A (es) | Derivados de hidroxipiridona, composiciones farmceuticas de los mismos y su uso terapeutico para tratar enfermedades proliferativas. | |
| KR20160135230A (ko) | 암의 치료를 위한 병용 요법으로서의 에리불린 및 mTOR 억제제의 용도 | |
| BR112013018598A2 (pt) | composição farmacêutica, método para tratar uma doença cardíaca, uso de (s)-metil-3-[4-(2-hidroxi-3-[4-(2-hidroxi-3-isopropilamino) propoxi] fenilpropionato, e, método para controlar frequência cardíaca | |
| JP2021105005A (ja) | 癌治療 | |
| Li et al. | Targeting autophagy-related epigenetic regulators for cancer drug discovery | |
| BR112012020060A2 (pt) | composto de fórmula (i) ou um sal farmaceuticamente aceitável do mesmo, uso do mesmo na fabricação de um medicamento, composição farmacêutica e método para o tratamento de demência em um sujeito animal incluindo um sujeito mamífero. | |
| Ha et al. | Targeting stress induction of GRP78 by cardiac glycoside oleandrin dually suppresses cancer and COVID-19 | |
| BR112013029146A2 (pt) | composto, composição farmacêutica, e, kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B11A | Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing | ||
| B11Y | Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired |